Diazepam administration after prolonged status epilepticus reduces neurodegeneration in the amygdala but not in the hippocampus during epileptogenesis
about
The limitations of diazepam as a treatment for nerve agent-induced seizures and neuropathology in rats: comparison with UBP302.The recovery of acetylcholinesterase activity and the progression of neuropathological and pathophysiological alterations in the rat basolateral amygdala after soman-induced status epilepticus: relation to anxiety-like behavior.Contribution of amygdala pathology to comorbid emotional disturbances in temporal lobe epilepsy.Higher susceptibility of the ventral versus the dorsal hippocampus and the posteroventral versus anterodorsal amygdala to soman-induced neuropathology.The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.Neuroprotective efficacy of caramiphen against soman and mechanisms of its action.Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administrationFinding new cures for neurological disorders: a possible fringe benefit of biodefense research?Convulsive status epilepticus duration as determinant for epileptogenesis and interictal discharge generation in the rat limbic system.Glial source of nitric oxide in epileptogenesis: A target for disease modification in epilepsy.Susceptibility to Soman Toxicity and Efficacy of LY293558 Against Soman-Induced Seizures and Neuropathology in 10-Month-Old Male Rats.Status Epilepticus: Behavioral and Electroencephalography Seizure Correlates in Kainate Experimental Models.Comparing the Antiseizure and Neuroprotective Efficacy of LY293558, Diazepam, Caramiphen, and LY293558-Caramiphen Combination against Soman in a Rat Model Relevant to the Pediatric Population.
P2860
Q30399944-A3A7EFE7-7A9D-4C85-9232-96CC62360C17Q30410510-0AC53FB7-C87B-42AA-8322-1CEDDEF54F7DQ31015121-6C73E008-6B25-4EDF-9E39-0EC7CB61393CQ34106485-04502730-A3B0-4C22-AA8D-E43120DC3F52Q34552059-38CB3648-3A43-4329-BD01-54AE677168C7Q35564288-9E0AFB25-180B-4A66-95C7-AD710150FEE3Q36497607-B2578423-EB8A-4CA3-8496-112F704FD98EQ37726564-6B8F51FE-4A2A-409B-A86D-359B4A97FA91Q41842500-D401255C-52BA-4E3B-9520-6A1B89B3AE25Q47920504-29FD5D76-D414-478B-A3E7-D1F21436FAB0Q48166589-6BFA11D5-7509-443A-9589-61FC987083A0Q49310896-6164F807-A342-4839-BD31-EBCD4A1A12BBQ51749309-95A8C23D-FD3F-49C2-85CC-BEFA33B2E3A5
P2860
Diazepam administration after prolonged status epilepticus reduces neurodegeneration in the amygdala but not in the hippocampus during epileptogenesis
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Diazepam administration after ...... ocampus during epileptogenesis
@ast
Diazepam administration after ...... ocampus during epileptogenesis
@en
type
label
Diazepam administration after ...... ocampus during epileptogenesis
@ast
Diazepam administration after ...... ocampus during epileptogenesis
@en
prefLabel
Diazepam administration after ...... ocampus during epileptogenesis
@ast
Diazepam administration after ...... ocampus during epileptogenesis
@en
P2093
P2860
P1433
P1476
Diazepam administration after ...... ocampus during epileptogenesis
@en
P2093
Felicia Qashu
James P Apland
Maria F M Braga
Taiza H Figueiredo
Vassiliki Aroniadou-Anderjaska
P2860
P2888
P304
P356
10.1007/S00726-008-0227-2
P577
2009-01-07T00:00:00Z